Fiche société
Merck Sharp & Dohme LLC
Traitements, essais et publications liés.
Traitements117programmes
Essais64liés
Publications99liées
SourceDBlocale
Traitements
117| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 5-Fluorouracil (5-FU)This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| 5-FUThe study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS). | Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Belgium, Brazil, Canada, Chile, China, Czechia, … | À vérifier |
| 5-hydroxytryptamine subtype 3 receptor antagonistResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| AcetaminophenThis study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids. | Cancer, Lupus | Phase 2/3 | À vérifier | Canada, Denmark, France, Greece, Israel, Italy, Japan, Netherlands, … | À vérifier |
| AtezolizumabThis phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach. | Cancer | Phase 1/2 | United States, Argentina, Chile, China, Germany, Greece, Israel, Italy, … | À vérifier | |
| ATRASubstudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021. | Parkinson | Phase 1/2 | À vérifier | United States, Australia, France, Israel, Italy, South Africa, Switzerland | À vérifier |
| BCGResearchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab. | Parkinson | Phase 3 | Traitement symptomatique | United States, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, … | À vérifier |
| BelzutifanThe goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants. | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, … | À vérifier |
| BlinatumomabThe goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients. The main questions it aims to answer are: * Does Blinatumomab improve patients' clinical symptoms? * Is Blinatumomab safe for the treatment of myasthenia gravis? Participants will: * Receive two cycles of intravenous Blinatumomab infusion, each lasting 5 days, with a 1-week interval between cycles. * Visit the clinic once every 4 weeks for checkups and tests. * Keep a diary of their symptoms and the types and dosages of medications. | Cancer, Lupus, Myasthénie, SEP | Phase 2/3 | Traitement symptomatique | Canada, Denmark, France, Greece, Israel, Italy, Japan, Netherlands, … | À vérifier |
| Blood Sample CollectionThis study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants. | Parkinson | À vérifier | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, … | À vérifier |
| BoserolimabThe purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study. | Parkinson | Phase 1/2 | À vérifier | United States, Canada, Hungary, Israel, Italy, Poland, South Korea, Spain, … | À vérifier |
| CabozantinibThere will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort. In the Combination Dose Finding cohort and the Combination Expansion cohort, we will combine cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer (CRC). In the Monotherapy MET Amplified cohort, we will screen at least 50 patients for MET gene amplification ("MET amplification"). Patients with MET amplification will receive cabozantinib only (monotherapy). The primary objective of this open-label phase Ib trial are: 1. To determine the maximum tolerated dose and the recommended phase II dose for the combination of cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer and 2. To identify the objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer. The secondary objectives are: 1. To describe the non-dose limiting toxicities of cabozantinib and panitumumab. 2. To describe the clinical activity (ORR, PFS, OS) of cabozantinib and panitumumab. 3. To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer. 4. To describe the clinical activity (PFS, OS) of cabozantinib monotherapy in patients with MET amplified colorectal cancer. | Cancer, Lupus, SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| CalderasibThis is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calderasib plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS). | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Brazil, China, France, Germany, Greece, … | À vérifier |
| Cisplatin 100 mg/m^2This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| corticosteroidThe goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN). | Lupus, Parkinson | Phase 2 | À vérifier | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| DocetetaxelResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| EtoposideThe purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study. | Cancer, Myasthénie, Parkinson, SEP | Phase 1/2 | À vérifier | United States, Argentina, Chile, China, Germany, Greece, Israel, Italy, … | À vérifier |
| Etoposide 100 mg/m^2Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| External Beam Radiotherapy (EBRT)The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Austria, Belgium, Canada, Chile, China, Colombia, … | À vérifier |
| Favezelimab/PembrolizumabSubstudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study. | Parkinson | Phase 1/2 | À vérifier | United States, Australia, Canada, Chile, France, Hungary, Israel, Netherlands, … | À vérifier |
| Fludrocortisone acetateThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, … | À vérifier |
| GocatamigResearchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away | Cancer | Phase 1/2 | United States, Argentina, Chile, China, Germany, Greece, Israel, Italy, … | À vérifier | |
| HER3-DXdThis is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| I-DXdResearchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away | Cancer | Phase 1/2 | United States, Argentina, Chile, China, Germany, Greece, Israel, Italy, … | À vérifier | |
| Ifinatamab DeruxtecanResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| IntismeranResearchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC. | Cancer | Phase 3 | United States, Australia, Brazil, Canada, Chile, Colombia, France, Germany, … | À vérifier | |
| IrinotecanThe irinotecan and cisplatin combination showed significant anti-tumor activity. In the first-line setting, the investigators showed that this regimen had significant anti-tumor activity in 47% of chemo-naïve NSCLC patients with 1-year survival rate of 64.2%. Again, the investigators showed that the second-line Irinotecan and cisplatin is an active and well-tolerated regimen in patients with advanced NSCLC pretreated with non-platinum based chemotherapy. TS-1 (Jeil Pharmaceutical Co.,Ltd, Seoul, Korea) is an oral anticancer drug comprised of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug that generates 5-fluorouracil (5-FU) in blood via metabolism by liver enzyme, and 5-chloro-2, 4-dihydroxypyridine enhance the serum concentration of 5-FU by the competitive inhibition of dihydropyrimidine dehydrogenase, an enzyme responsible for 5-FU catabolism. Potassium oxonate is also a reversible competitive inhibitor of orotate phosphoribosyl transferase, a phosphoenzyme for 5-FU. Diarrhea induced by 5-FU administration is though to be attributable to the phosphorylation of 5-FU by the enzyme in the gastrointestinal tissue. After oral administration of potassium oxonate, the concentration of potassium in the gastrointestinal tissue is high enough to inhibit the enzyme while the concentration in blood and tumor is reported to be either slight or nil. Because of these mechanism, oral TS-1 administration generates a higher concentration of 5-FU than protracted intravenous infusion of 5-FU given in a dose equimolar to the tegafur in S-1, whereas the incidence of adverse events concerning the GI tract does not increase. In a phase II trial of TS-1 as first-line setting in NSCLC, the response rate was 22% and the median survival time was 10.2 months. As expected, the incidence of severe gastrointestinal adverse events was low, and so was few severe hematologic toxicity. Recently 3-weekly TS-1 plus cisplatin showed activity against NSCLC with a response rate of 32.7% and the safety was acceptable. | Cancer, Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, Germany, Italy, Japan, Norway, … | À vérifier |
| LenvatinibThe purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC). The primary hypotheses for this study are that: 1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and 2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS). Based on recommendation of the external Data Monitoring Committee (eDMC), Amendment 3 (effective: September \[Sep\]-24-2021) was implemented to unblind the study and discontinue lenvatinib and placebo treatment. The eDMC was then disbanded. With Amendment 4 (effective: December-5-2022) second course pembrolizumab will no longer be offered. Any participant receiving second course pembrolizumab treatment prior to initiation of Amendment 4 will be able to complete treatment as planned. Study participation will end after the final administration of pembrolizumab. Participants who either complete 35 administrations of pembrolizumab or discontinue pembrolizumab will discontinue from the study following the safety follow-up visit. AEs and spontaneously reported pregnancies will be reported and followed per protocol. The overall study ends when the last participant completes the last study-related contact or visit, withdraws from the study, or is lost to follow-up. | Cancer, Parkinson, SEP | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, … | À vérifier |
| LeucovorinThis is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Cancer, Parkinson, SEP | Phase 3 | À vérifier | United States, Argentina, Belgium, Brazil, Canada, Chile, China, Czechia, … | À vérifier |
| LevoleucovorinThis is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Belgium, Brazil, Canada, Chile, China, Czechia, … | À vérifier |
| MK-0472The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Chile, Israel, Poland, Spain, Switzerland | À vérifier |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Cancer, Lupus | Phase 1 | À vérifier | Australia, Belgium, China, Colombia, Georgia, Italy, Japan, Moldova, … | À vérifier |
| MK-1084The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Chile, Israel, Poland, Spain, Switzerland | À vérifier |
| MK-1484The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Israel, Netherlands | À vérifier |
| MK-2214Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it | Alzheimer | Phase 2 | À vérifier | United States, Argentina, Australia, Belgium, Canada, Japan, Netherlands, Singapore, … | À vérifier |
| MK-4830The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, Germany, Italy, Japan, Norway, … | À vérifier |
| MK-6194The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus. | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, Canada, Chile, China, Colombia, France, … | À vérifier |
| Nab-paclitaxelThe purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1). | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, … | À vérifier |
| Neurokinin-1 receptor antagonistResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| Olaparib 300 mg BIDResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| OpevesostatThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, … | À vérifier |
| Pembrolizumab coformulated with berahyaluronidase alfaResearchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC. | Cancer | Phase 3 | United States, Australia, Brazil, Canada, Chile, Colombia, France, Germany, … | À vérifier | |
| Pembrolizumab/QuavonlimabThe goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants. | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, … | À vérifier |
| pembrolizumab/vibostolimabResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab. | Parkinson | Phase 3 | À vérifier | United States, Brazil, Canada, Chile, China, Dominican Republic, Guatemala, Hong Kong, … | À vérifier |
| Platinum, investigator's choiceResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| Prednisone acetateThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, … | À vérifier |
| QuavonlimabSubstudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021. | Parkinson | Phase 1/2 | À vérifier | United States, Australia, France, Israel, Italy, South Africa, Switzerland | À vérifier |
| R-DXdResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care. | Cancer | Phase 3 | À vérifier | À vérifier | |
| RadiotherapyEvery year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed. | Cancer, Parkinson, SEP | Phase 3 | Traitement symptomatique | United States, Argentina, Belgium, Brazil, Canada, Chile, China, Czechia, … | À vérifier |
| Radiotherapy 60 GrayThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Radiotherapy 66 GrayThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Radiotherapy 70 GrayThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Raludotatug DeruxtecanResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, … | À vérifier |
| Rescue MedicationResearchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy. | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, … | À vérifier |
| Rescue MedicationsResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care. | Cancer, Parkinson | Phase 1/2 | À vérifier | United States, Argentina, Chile, China, Germany, Greece, Israel, Italy, … | À vérifier |
| Rescue medications for chemotherapyResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, … | À vérifier |
| Rescue medications for sacituzumab tirumotecanResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, … | À vérifier |
| Rituximab biosimilarResearchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy) | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Israel, Spain, Taiwan, Turkey (Türkiye) | À vérifier |
| S-1The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS). | Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer, Parkinson | Phase 3 | À vérifier | United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, … | À vérifier |
| Sacituzumab Tirumotecan (sac-TMT)This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study. | Parkinson | Phase 1/2 | À vérifier | United States, Brazil, Chile, China, France, Germany, Italy, Norway, … | À vérifier |
| SotaterceptResearchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH). This trial focuses on CpcPH that is related to heart failure with preserved ejection fraction (HFpEF). The goal of the study is to learn if participants who receive sotatercept live longer without their CpcPH-HFpEF getting worse than those who receive placebo. | Insuffisance cardiaque, Maladie coronarienne | Phase 3 | À vérifier | À vérifier | |
| Standard Thoracic RadiotherapyResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, … | À vérifier |
| Supportive care measuresThis is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC). Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, … | À vérifier |
| Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients. | Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, … | À vérifier |
| TACEThe purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS). | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, Colombia, Denmark, France, … | À vérifier |
| TelcagepantThe purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Telcagepant 140 mgA study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine. | Migraine | Phase 2 | À vérifier | À vérifier | |
| Telcagepant 280 mgA study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine. | Migraine | Phase 2 | À vérifier | À vérifier | |
| Tumor Tissue CollectionThis study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants. | Parkinson | À vérifier | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, … | À vérifier |
| Vericiguat suspensionThis study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period. | Insuffisance cardiaque, Maladie coronarienne | Phase 2/3 | À vérifier | United States, Belgium, Brazil, Canada, Colombia, Croatia, Denmark, Finland, … | À vérifier |
| Vericiguat tabletThis study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period. | Insuffisance cardiaque, Maladie coronarienne | Phase 2/3 | À vérifier | United States, Belgium, Brazil, Canada, Colombia, Croatia, Denmark, Finland, … | À vérifier |
| VibostolimabSubstudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021. | Parkinson | Phase 1/2 | À vérifier | United States, Canada, Hungary, Israel, Italy, Poland, South Korea, Spain, … | À vérifier |
| Vibostolimab/PembrolizumabSubstudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study. | Parkinson | Phase 1/2 | À vérifier | United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, … | À vérifier |
| VinflunineResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, … | À vérifier |
| BlinatumomabThe goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients. The main questions it aims to answer are: * Does Blinatumomab improve patients' clinical symptoms? * Is Blinatumomab safe for the treatment of myasthenia gravis? Participants will: * Receive two cycles of intravenous Blinatumomab infusion, each lasting 5 days, with a 1-week interval between cycles. * Visit the clinic once every 4 weeks for checkups and tests. * Keep a diary of their symptoms and the types and dosages of medications. | Myasthénie | Phase 2 | Traitement symptomatique | À vérifier | |
| TelcagepantThe purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Telcagepant 140 mgA study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine. | Migraine | Phase 2 | À vérifier | À vérifier | |
| IrinotecanThe irinotecan and cisplatin combination showed significant anti-tumor activity. In the first-line setting, the investigators showed that this regimen had significant anti-tumor activity in 47% of chemo-naïve NSCLC patients with 1-year survival rate of 64.2%. Again, the investigators showed that the second-line Irinotecan and cisplatin is an active and well-tolerated regimen in patients with advanced NSCLC pretreated with non-platinum based chemotherapy. TS-1 (Jeil Pharmaceutical Co.,Ltd, Seoul, Korea) is an oral anticancer drug comprised of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug that generates 5-fluorouracil (5-FU) in blood via metabolism by liver enzyme, and 5-chloro-2, 4-dihydroxypyridine enhance the serum concentration of 5-FU by the competitive inhibition of dihydropyrimidine dehydrogenase, an enzyme responsible for 5-FU catabolism. Potassium oxonate is also a reversible competitive inhibitor of orotate phosphoribosyl transferase, a phosphoenzyme for 5-FU. Diarrhea induced by 5-FU administration is though to be attributable to the phosphorylation of 5-FU by the enzyme in the gastrointestinal tissue. After oral administration of potassium oxonate, the concentration of potassium in the gastrointestinal tissue is high enough to inhibit the enzyme while the concentration in blood and tumor is reported to be either slight or nil. Because of these mechanism, oral TS-1 administration generates a higher concentration of 5-FU than protracted intravenous infusion of 5-FU given in a dose equimolar to the tegafur in S-1, whereas the incidence of adverse events concerning the GI tract does not increase. In a phase II trial of TS-1 as first-line setting in NSCLC, the response rate was 22% and the median survival time was 10.2 months. As expected, the incidence of severe gastrointestinal adverse events was low, and so was few severe hematologic toxicity. Recently 3-weekly TS-1 plus cisplatin showed activity against NSCLC with a response rate of 32.7% and the safety was acceptable. | Cancer | Phase 1 | À vérifier | South Korea | À vérifier |
| MK-1484The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Israel, Netherlands | À vérifier |
| OpevesostatThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czechia, Estonia, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, … | À vérifier |
| MK-6194The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus. | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, Canada, Chile, China, Colombia, France, Guatemala, Italy, Japan, Malaysia, Mexico, Philippines, Poland, Spain, Turkey (Türkiye) | À vérifier |
| MK-0472The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors. | Parkinson | Phase 1 | À vérifier | United States, Canada, Chile, Israel, Poland, Spain, Switzerland | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Israel, Italy, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 1 | À vérifier | Japan | À vérifier |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Lupus | Phase 1 | À vérifier | Australia, Belgium, China, Colombia, Georgia, Italy, Japan, Moldova, Peru, Romania, Thailand | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, … | À vérifier |
| MK-2214Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it | Alzheimer | Phase 2 | À vérifier | United States, Argentina, Australia, Belgium, Canada, Japan, Netherlands, Singapore, South Korea, Spain, United Kingdom | À vérifier |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Cancer | Phase 2/3 | À vérifier | United States, Argentina, Israel, Spain, Taiwan, Turkey (Türkiye) | À vérifier |
| AtezolizumabThis phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach. | Cancer | Phase 3 | United States | À vérifier | |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, China, France, Greece, Israel, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom | À vérifier |
| RadiotherapyEvery year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed. | Cancer | À vérifier | Traitement symptomatique | Canada | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Greece, Hungary, Ireland, Israel, Italy, Japan, Norway, … | À vérifier |
| Raludotatug DeruxtecanResearchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments | Parkinson | Phase 2 | Immunomodulation | United States, Chile, Germany, Greece, Hungary, Israel, Italy, Poland, Spain, Turkey (Türkiye) | À vérifier |
| Tumor Tissue CollectionThis study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants. | Parkinson | À vérifier | À vérifier | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, Ukraine | À vérifier |
| pembrolizumab/vibostolimabResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Chile, China, Costa Rica, Czechia, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Malaysia, Mexico, Philippines, Portugal, Romania, … | À vérifier |
| R-DXdResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care. | Cancer | Phase 3 | À vérifier | À vérifier | |
| LenvatinibThe purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC). The primary hypotheses for this study are that: 1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and 2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS). Based on recommendation of the external Data Monitoring Committee (eDMC), Amendment 3 (effective: September \[Sep\]-24-2021) was implemented to unblind the study and discontinue lenvatinib and placebo treatment. The eDMC was then disbanded. With Amendment 4 (effective: December-5-2022) second course pembrolizumab will no longer be offered. Any participant receiving second course pembrolizumab treatment prior to initiation of Amendment 4 will be able to complete treatment as planned. Study participation will end after the final administration of pembrolizumab. Participants who either complete 35 administrations of pembrolizumab or discontinue pembrolizumab will discontinue from the study following the safety follow-up visit. AEs and spontaneously reported pregnancies will be reported and followed per protocol. The overall study ends when the last participant completes the last study-related contact or visit, withdraws from the study, or is lost to follow-up. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Brazil, Chile, China, Colombia, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Puerto Rico, … | À vérifier |
| Sacituzumab TirumotecanResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Peru, Poland, Portugal, South Korea, … | À vérifier |
| MK-2214Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| OpevesostatThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, … | À vérifier |
| pembrolizumab/vibostolimabResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab. | Parkinson | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, New Zealand, Poland, South Africa, … | À vérifier |
| CalderasibThis is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calderasib plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS). | Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, France, Georgia, Germany, Greece, India, Italy, Japan, Mexico, Netherlands, New Zealand, Philippines, … | À vérifier |
| pembrolizumab/vibostolimabResearchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab. | Parkinson | Phase 3 | À vérifier | United States, Brazil, Canada, Chile, China, Dominican Republic, Guatemala, Hong Kong, Hungary, India, Japan, Malaysia, Mexico, Peru, Philippines, Romania, Russia, South Africa, South Korea, Thailand, … | À vérifier |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Cancer | Phase 1/2 | À vérifier | United States, Argentina, Australia, Canada, Chile, China, Germany, Israel, Italy, Poland, South Korea, Spain, Turkey (Türkiye), United Kingdom | À vérifier |
| CalderasibThis is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calderasib plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS). | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Brazil, China, France, Germany, Greece, Italy, Japan, Netherlands, Poland, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom | À vérifier |
| AtezolizumabThis phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach. | Cancer | Phase 2 | United States | À vérifier | |
| AcetaminophenThis study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids. | Cancer | Phase 2 | Traitement symptomatique | France | À vérifier |
| SotaterceptResearchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH). This trial focuses on CpcPH that is related to heart failure with preserved ejection fraction (HFpEF). The goal of the study is to learn if participants who receive sotatercept live longer without their CpcPH-HFpEF getting worse than those who receive placebo. | Insuffisance cardiaque | Phase 3 | À vérifier | À vérifier | |
| MK-1045This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts). | Cancer | Phase 2/3 | À vérifier | Canada, Denmark, France, Greece, Israel, Italy, Japan, Netherlands, Spain, Sweden | À vérifier |
| IntismeranResearchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC. | Cancer | Phase 3 | United States, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, Poland, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom | À vérifier | |
| Vericiguat tabletThis study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period. | Maladie coronarienne | Phase 2/3 | À vérifier | United States, Belgium, Brazil, Canada, Colombia, Croatia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Malaysia, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, … | À vérifier |
| BelzutifanThe goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Ireland, Italy, Japan, Netherlands, Poland, Romania, … | À vérifier |
| AtezolizumabThis phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach. | Cancer | Phase 2 | United States, Puerto Rico | À vérifier | |
| GocatamigResearchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away | Cancer | Phase 1/2 | United States, Argentina, Chile, China, Germany, Greece, Israel, Italy, Poland, South Korea, Spain, Thailand, Turkey (Türkiye) | À vérifier |
Essais cliniques
64| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Gocatamig | Cancer | Phase 1/2 | NCT07227597 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | RECRUITING |
| Atezolizumab | Cancer | Phase 2 | NCT06096779 | Kirros — A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | ACTIVE_NOT_RECRUITING |
| Belzutifan | Cancer | Phase 3 | NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | ACTIVE_NOT_RECRUITING |
| Vericiguat tablet | Maladie coronarienne | Phase 2/3 | NCT05714085 | Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | RECRUITING |
| Intismeran | Cancer | Phase 3 | NCT07513376 | INTerpath-014 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | RECRUITING |
| MK-1045 | Cancer | Phase 2/3 | NCT07570173 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | COMPLETED |
| Sotatercept | Insuffisance cardiaque | Phase 3 | NCT07839585 | CHORUS — A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041) | NOT_YET_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03711032 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | ACTIVE_NOT_RECRUITING |
| Acetaminophen | Cancer | Phase 2 | NCT00712712 | MEDOR — Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer | COMPLETED |
| Atezolizumab | Cancer | Phase 2 | NCT03141684 | Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma | ACTIVE_NOT_RECRUITING |
| Calderasib | Cancer | Phase 3 | NCT07554339 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03924856 | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) | COMPLETED |
| MK-1045 | Cancer | Phase 1/2 | NCT07519772 | WaveSpan-008 — A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | COMPLETED |
| pembrolizumab/vibostolimab | Parkinson | Phase 3 | NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | TERMINATED |
| Pembrolizumab | Parkinson | Phase 3 | NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 2 | NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | TERMINATED |
| Calderasib | Parkinson | Phase 3 | NCT06345729 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | RECRUITING |
| Pembrolizumab | Cancer | Phase 3 | NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | RECRUITING |
| pembrolizumab/vibostolimab | Parkinson | Phase 3 | NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | TERMINATED |
| Pembrolizumab 200 mg | Parkinson | Phase 3 | NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | ACTIVE_NOT_RECRUITING |
| Opevesostat | Cancer | Phase 3 | NCT06136624 | OMAHA-003 — Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | RECRUITING |
| MK-2214 | Alzheimer | Phase 1 | NCT05466422 | A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) | COMPLETED |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06170788 | TroFuse-007 — Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | RECRUITING |
| Ramucirumab | Parkinson | Phase 1/2 | NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | RECRUITING |
| Lenvatinib | Cancer | Phase 3 | NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | TERMINATED |
| R-DXd | Cancer | Phase 3 | NCT07776691 | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) | NOT_YET_RECRUITING |
| pembrolizumab/vibostolimab | Parkinson | Phase 3 | NCT05298423 | KEYVIBE-006 — Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | RECRUITING |
| paclitaxel | Parkinson | Phase 1/2 | NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | RECRUITING |
| Tumor Tissue Collection | Parkinson | À vérifier | NCT04165798 | KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | RECRUITING |
| Raludotatug Deruxtecan | Parkinson | Phase 2 | NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | COMPLETED |
| Sacituzumab Tirumotecan | Cancer | Phase 3 | NCT07318558 | TroFuse-021 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | RECRUITING |
| Pembrolizumab 200 mg | Parkinson | Phase 3 | NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | ACTIVE_NOT_RECRUITING |
| Sacituzumab Tirumotecan | Cancer | Phase 3 | NCT06312137 | TroFuse-019 — A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | RECRUITING |
| Radiotherapy | Cancer | À vérifier | NCT04115267 | Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies | RECRUITING |
| Sacituzumab Tirumotecan | Cancer | Phase 3 | NCT07419295 | TroFuse-031 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | RECRUITING |
| Atezolizumab | Cancer | Phase 3 | NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | RECRUITING |
| MK-1045 | Cancer | Phase 2/3 | NCT07634471 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | RECRUITING |
| MK-2214 | Alzheimer | Phase 2 | NCT07033494 | A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06312176 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | ACTIVE_NOT_RECRUITING |
| MK-1045 | Lupus | Phase 1 | NCT07363590 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 1 | NCT06049212 | TroFuse-008 — Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | ACTIVE_NOT_RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | RECRUITING |
| MK-0472 | Parkinson | Phase 1 | NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | RECRUITING |
| MK-6194 | Lupus | Phase 2 | NCT06161116 | Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) | TERMINATED |
| Opevesostat | Cancer | Phase 3 | NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | RECRUITING |
| MK-1484 | Parkinson | Phase 1 | NCT05382325 | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | TERMINATED |
| Pembrolizumab | Parkinson | Phase 3 | NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 2 | NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | COMPLETED |
| Irinotecan | Cancer | Phase 1 | NCT00874328 | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | UNKNOWN |
| Telcagepant 140 mg | Migraine | Phase 2 | NCT00797667 | MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) | TERMINATED |
| Telcagepant | Migraine | Phase 3 | NCT00662818 | Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 3 | NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | COMPLETED |
| Blinatumomab | Myasthénie | Phase 2 | NCT06836973 | Blinatumomab for Treatment of Refractory Myasthenia Gravis | NOT_YET_RECRUITING |
Publications
99| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Radiotherapy 70 Gray | Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC. | Clinical cancer research : an official journal of the American Association for Cancer Research | ||
| Radiotherapy 70 Gray | Retrospective Analysis of Survival and Adverse Effects Associated With Stereotactic Body Radiation Therapy in 12 Dogs With Hepatocellular Carcinoma. | Veterinary and comparative oncology | ||
| Radiotherapy 70 Gray | Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer. | The Prostate | ||
| Cisplatin 100 mg/m^2 | Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. | Lancet (London, England) | ||
| Cisplatin 100 mg/m^2 | Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | ||
| Cisplatin 100 mg/m^2 | Superselective intra-arterial chemoradiotherapy for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212. | ESMO open | ||
| Telcagepant 280 mg | Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. | Headache | ||
| Telcagepant 140 mg | Randomized, controlled trial of telcagepant over four migraine attacks. | Cephalalgia : an international journal of headache | ||
| Telcagepant | Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. | Neurology | ||
| Supportive care measures | POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management. | American journal of hematology | ||
| Supportive care measures | Nuances of Perioperative Therapy in Gingivobuccal Cancers. | Oral and maxillofacial surgery clinics of North America | ||
| Supportive care measures | Targeting the virus-host interface for the development of therapeutics against filoviruses. | Current opinion in virology | ||
| Rescue Medication | Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. | Lancet (London, England) | ||
| Rescue Medication | Living with Dravet syndrome: quality of life and caregiver burden among family caregivers in Europe. Results from the QoL4DRAVET study. | Epilepsy & behavior : E&B | ||
| Rescue Medication | Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis. | The Journal of dermatological treatment | ||
| corticosteroid | Benralizumab effectiveness in a real-world Portuguese severe eosinophilic asthma population: BETREAT study. | Pulmonology | ||
| corticosteroid | Comment on: 'Ultrasound-guided injection strategies for lateral epicondylitis-a multicenter randomized comparison of corticosteroid, platelet-rich plasma, and ozone'. | Future science OA | ||
| corticosteroid | Implantable starch-based extrudates for controlled release of corticosteroids. | International journal of pharmaceutics: X | ||
| Blinatumomab | Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus. | Cancer | ||
| Blinatumomab | Derivation of an occupational exposure limit (OEL) for a potent bispecific protein-Blinatumomab (BLINCYTO®). | Regulatory toxicology and pharmacology : RTP | ||
| Blinatumomab | Cytokine release syndrome mimicking drug reaction with eosinophilia and systemic syndrome (DRESS) in a patient on blinatumomab therapy. | JAAD case reports | ||
| Rituximab biosimilar | A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy. | BMC pharmacology & toxicology | ||
| Rituximab biosimilar | Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center. | Clinics (Sao Paulo, Brazil) | ||
| Rituximab biosimilar | Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare. | Journal of medical economics | ||
| Belzutifan | Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD). | Cancer metastasis reviews | ||
| Belzutifan | HIF-2α/TRIB3/PARP1 axis promotes progression by orchestrating DNA repair in clear cell renal cell carcinoma. | Biochimica et biophysica acta. Molecular basis of disease | ||
| Prednisone acetate | Oral AA amyloidosis with granulomatous cheilitis: a case report and literature review. | Clinical rheumatology | ||
| Prednisone acetate | [Ameliorative effects and mechanisms of Buyang Huanwu Decoction and its different ethanol elution fractions on pulmonary fibrosis model rats]. | Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica | ||
| Prednisone acetate | E-cigarette or vaping product use-associated lung injury without pulmonary symptoms: A case report and literature review. | Medicine | ||
| Fludrocortisone acetate | Coenzyme Q alleviates oxidative stress, inflammation and fibrosis via activation of TGFβ1/TNF-α in FCA-Salt hypertensive rats. | Archives of biochemistry and biophysics | ||
| Fludrocortisone acetate | Process optimization of hot-melt extruded filaments for FDM 3D printing of personalized low-dose fludrocortisone acetate oral dosage forms. | International journal of pharmaceutics | ||
| Fludrocortisone acetate | Feline hypoadrenocorticism: Emerging insights into clinical features, diagnosis, and treatment. | Schweizer Archiv fur Tierheilkunde | ||
| Opevesostat | Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. | Future oncology (London, England) | ||
| Opevesostat | Design, synthesis, and biological evaluation of cytochrome P450 CYP11A1 inhibitors. | Bioorganic & medicinal chemistry letters | ||
| Irinotecan | Corrigendum to 'Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells' [Biomaterials 72 (2015) 17043]. | Biomaterials | ||
| Irinotecan | In depth study on the mechanism of Xiao-Chai-Hu-Tang in ameliorating irinotecan-induced intestinal toxicity and enhancing antitumor immunity via intestinal microbiota and fecal metabolomics. | Journal of pharmaceutical and biomedical analysis | ||
| Cabozantinib | Deferred Cytoreductive Nephrectomy With Partial Hepatectomy for Giant Renal Cell Carcinoma of the Right Kidney With Extensive Hepatic Invasion: A Case Report in the Era of Systemic Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. | IJU case reports | ||
| Cabozantinib | Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study. | Oncoimmunology | ||
| MK-1084 | From KRAS to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design. | Journal of medicinal chemistry | ||
| MK-1084 | A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science. | Cancer investigation | ||
| Sacituzumab Tirumotecan | Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis. | Frontiers in immunology | ||
| Sacituzumab Tirumotecan | Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | ||
| Sacituzumab Tirumotecan | TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. | Future oncology (London, England) | ||
| Nab-paclitaxel | Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. | Advances in radiation oncology | ||
| Nab-paclitaxel | Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report. | Human vaccines & immunotherapeutics | ||
| Nab-paclitaxel | Estimating the cost-effectiveness of tumor treating fields for locally advanced pancreatic cancer patients. | Journal of medical economics | ||
| 5-Fluorouracil (5-FU) | Exosome-like nanoparticles derived from co-decoction enhance oral bioavailability and provide synergistic efficacy and reduced toxicity in combination with 5-fluorouracil for lung cancer therapy. | International journal of pharmaceutics: X | ||
| Leucovorin | Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. | International journal of cancer | ||
| Leucovorin | Domain-specific cognitive impairments following oxaliplatin and 5-fluorouracil treatment in rats: A preclinical study. | Behavioural brain research | ||
| Leucovorin | Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer. | Annals of medicine | ||
| Etoposide | DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL co-culture system. | Genes & diseases | ||
| Etoposide | . | Gut microbes | ||
| MK-4830 | A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report. | SAGE open medical case reports | ||
| ATRA | All-trans retinoic acid and lansoprazole potentiated NKG2D-CAR T for breast cancer treatment. | International immunopharmacology | ||
| ATRA | Naja atra SVPLA upregulates hexokinase 2-driven macrophage M1 polarization via the cGAS-STING signaling activation. | Toxicon : official journal of the International Society on Toxinology | ||
| ATRA | Acute leukemia during pregnancy: a single center experience with 23 cases, 2012-2022 and literature review. | Annals of medicine | ||
| Vibostolimab | Beyond empiric checkpoint escalation: Insights from KEYVIBE-010. | Med (New York, N.Y.) | ||
| Lenvatinib | Integrative multi-omics profiling reveals DRG1 promotes hepatocellular carcinoma via c-Myc phosphorylation and facilitates lenvatinib resistance. | Cellular signalling | ||
| Lenvatinib | Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia. | Journal of medical economics | ||
| Lenvatinib | ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma. | Cancer biology & therapy | ||
| MK-1045 | Phytoconstituents and Bioactivity of Plants of the Genus L. (Rosaceae): A Review. | International journal of molecular sciences | ||
| corticosteroid | Prediction of Prolonged Length of Hospital Stay in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: An Interpretable Machine Learning Tool. | Journal of clinical medicine | ||
| MK-6194 | Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. | ImmunoHorizons | ||
| Blinatumomab | Dynamics of in vivo immune remodeling in Ph all patients receiving frontline ponatinib and blinatumomab therapy. | Blood cancer journal | ||
| Blinatumomab | Fatal Neuroinvasive Astrovirus VA1 Encephalitis in a Child With High-Risk B-ALL Receiving Blinatumomab. | Pediatric blood & cancer | ||
| Cabozantinib | Antineoplastic and Immunomodulatory Effects of Cabozantinib in Continuous and Primary Human Anaplastic Thyroid Cancer Cells. | Cancers | ||
| 5-Fluorouracil (5-FU) | Betulin Alleviates 5-Fluorouracil-Induced Intestinal Mucositis in Mice. | Nutrients | ||
| 5-Fluorouracil (5-FU) | Resveratrol Modulates Phosphatidylcholine Metabolism-Related Enzymes and Enhances Chemosensitivity in Colorectal Cancer Models. | International journal of molecular sciences | ||
| Levoleucovorin | Leucovorin Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma. | Anticancer research | ||
| Leucovorin | Leucovorin Dispensing to U.S. Children in 2025. | The New England journal of medicine | ||
| Sacituzumab Tirumotecan (sac-TMT) | Trophoblast cell-surface antigen 2-targeted "sacituzumab tirumotecan": a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer. | Translational lung cancer research | ||
| Etoposide | Amphiphilic Semisynthetic Triterpenoids Impair Survival Pathways and Suppress Clonogenic Growth in Multidrug-Resistant High-Risk Neuroblastoma. | International journal of molecular sciences | ||
| Etoposide | Immunoglobulin Superfamily Protein BTNL9 Functions as a Non-Canonical Transcriptional Regulator to Suppress NSCLC Through Cell Cycle and p53 Pathways. | International journal of molecular sciences | ||
| MK-4830 | KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. | Future oncology (London, England) | ||
| MK-4830 | Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient. | Frontiers in pharmacology | ||
| ATRA | DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy. | BMC cancer | ||
| ATRA | Systemic administration of all-trans retinoic acid modulated circulating immune cells but failed to improve healing in a preclinical model of musculoskeletal trauma. | Frontiers in immunology | ||
| Vibostolimab | Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C. | ESMO open | ||
| Vibostolimab | No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity. | Cancer | ||
| Quavonlimab | LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. | Future oncology (London, England) | ||
| Quavonlimab | Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. | Annals of oncology : official journal of the European Society for Medical Oncology | ||
| Lenvatinib | LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62-Keap1-Nrf2 pathway. | Cancer drug resistance (Alhambra, Calif.) | ||
| Lenvatinib | Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. | Lancet (London, England) | ||
| Telcagepant 280 mg | Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. | Headache | ||
| Telcagepant 140 mg | Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. | Neurology | ||
| Telcagepant 140 mg | Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. | Cephalalgia : an international journal of headache | ||
| Telcagepant | Blocking the CGRP Receptor: Differences across Human Vascular Beds. | Pharmaceuticals (Basel, Switzerland) | ||
| Telcagepant | CGRP receptor antagonists (gepants). | Handbook of clinical neurology | ||
| Lenvatinib | T cell-nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy. | Science advances | ||
| Lenvatinib | Plant-derived natural products against hepatocellular carcinoma: chemical diversity, mechanisms of action, and organ-based classification. | Natural product research | ||
| Cabozantinib | A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting. | The oncologist | ||
| Blinatumomab | Efficacy of blinatumomab for dermatomyositis/SLE overlap syndrome occurring after allogeneic hematopoietic stem cell transplant performed for acute lymphoblastic leukemia. | Bone marrow transplantation | ||
| Blinatumomab | Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. | Cancer | ||
| Cabozantinib | The HGF/c-Met Signaling Axis: A Master Regulator of Invasion and Metastasis in Oral Squamous Cell Carcinoma. | Journal of stomatology, oral and maxillofacial surgery | ||
| Cabozantinib | Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis. | Medical oncology (Northwood, London, England) | ||
| Cabozantinib | Sustained Disease Control of High-Risk Metastatic Renal Epithelioid Angiomyolipoma through Multimodal Treatment Including Repeated Thoracic Resection and Systemic Therapy: A Case Report. | Case reports in oncology | ||
| Cabozantinib | Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies. | Frontiers in endocrinology | ||
| Cabozantinib | The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. | European urology open science | ||
| Cabozantinib | Durable benefit in a crowded frontline landscape: final results for nivolumab-cabozantinib in metastatic renal cell carcinoma. | Translational andrology and urology |